About this Research Topic
Prostate cancer (PCa) is the most prevalent non-cutaneous malignancy and ranks as the second leading cause of cancer-related deaths among males. Recent research has highlighted that tumor progression in PCa is intricately linked to disruptions in the homeostasis of both cellular and non-cellular stromal components, which significantly influence tumor development. Studies have underscored the pivotal role of the prostate tumor microenvironment (TME) in the early stages of PCa, where it promotes epithelial cell tumorigenesis even in the absence of genetic mutations. Despite these findings, the mechanisms governing the interactions between stromal and epithelial cells in PCa remain inadequately described. Emerging evidence suggests that stromal cells may play a crucial role in the development of castration-resistant prostate cancer (CRPC). The tumor/stroma ratio and the expression of stromal markers are being explored as potential prognostic tools for assessing PCa progression and predicting therapeutic responses. In contrast, testicular germ cell tumors (TGCTs), though rare, primarily affect children and young adults. While TGCTs are generally curable, their incidence is on the rise, prompting increased attention to their molecular pathways. Recent in vitro and in vivo studies are delving into the molecular and epigenetic mechanisms of TGCTs, aiming to develop novel therapeutic strategies and identify new epigenetic biomarkers for improved prognostic and diagnostic capabilities.
This research topic aims to explore new potential biomarkers and cellular strategies for studying prostate and testicular cancer cells. The primary objectives include identifying novel biomarkers for prognosis, validating epigenetic biomarkers, and developing innovative therapeutic approaches. Additionally, the research seeks to elucidate the genes involved in tumor progression and other signaling pathways. By addressing these objectives, the research aims to enhance our understanding of the molecular underpinnings of these cancers and improve diagnostic and therapeutic outcomes.
To gather further insights into the molecular and cellular dynamics of prostate and testicular cancers, we welcome articles addressing, but not limited to, the following themes:
- Identification of novel biomarkers for prostate and testicular cancers prognosis.
- Experimental validation of epigenetic biomarkers for prostate and testicular tumors.
- New therapeutic approaches for prostate and testicular tumors, including natural bioactive molecules and hormone therapy for prostate cancer.
- Identification of genes involved in tumor progression and/or other signaling pathways.
This research topic aims to explore new potential biomarkers and cellular strategies for studying prostate and testicular cancer cells. The primary objectives include identifying novel biomarkers for prognosis, validating epigenetic biomarkers, and developing innovative therapeutic approaches. Additionally, the research seeks to elucidate the genes involved in tumor progression and other signaling pathways. By addressing these objectives, the research aims to enhance our understanding of the molecular underpinnings of these cancers and improve diagnostic and therapeutic outcomes.
To gather further insights into the molecular and cellular dynamics of prostate and testicular cancers, we welcome articles addressing, but not limited to, the following themes:
- Identification of novel biomarkers for prostate and testicular cancers prognosis.
- Experimental validation of epigenetic biomarkers for prostate and testicular tumors.
- New therapeutic approaches for prostate and testicular tumors, including natural bioactive molecules and hormone therapy for prostate cancer.
- Identification of genes involved in tumor progression and/or other signaling pathways.
Keywords: Biomarkers, prostate cancer, testicular cancer, cellular strategies, cell-based strategies
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
